Our new article on Fidaxomicin for 1st CDI episode in ICHs is now available on @OFIDJournal
11,204 pts with 1st CDI episode
2,362 ICHs
The Fidaxomicin group had lower CDI recurrence compared to vancomycin (aOR 0.44, 95%CI 0.21–0.96)
#TxID
academic.oup.com/ofid/article/d…
Early concordant Abx was not associated with 30day mortality in pts with CRAB bacteremia.
Whether this finding reflects the limited efficacy of colistin (predominant Abx) remains unclear. More effective therapeutic options for CRAB bacteremia are needed to improve pts outcomes.
Our retrospective study on the impact of early concordant Abx Tx on 30day mortality in 413 hospitalized pts with CRAB bacteremia. 30% received early concordant Tx while 70% received early discordant Tx. The 30-day mortality was 63%.>>
www.mdpi.com/2077-0383/14...
The 3rd International CMV Symposium kicks off today!
CMV, the troll of transplantation😈 is not gonna like this.
@kottonnelson.bsky.social
Invasive Candida infections in solid organ transplant recipients between 2008 and 2020
From the Swiss Transport Cohort Study
High rates of IC, predominately intra-abdominal, with decreasing incidence during the study period. Mortality remains high
www.amjtransplant.org/article/S160... #TxID
(higher ICU admission rates and longer hospital stays).
These findings suggest that obesity may complicate the clinical management of CDI.
www.mdpi.com/2077-0383/14...
This is a retrospective cohort study conducted in Beilinson - Rabin Medical Center that included 889 hospitalized patients with CDI.
We found that obesity was not independently associated with 90-day mortality. However, obese patients experienced more complicated clinical course
With both obesity and Clostridioides difficile infections (CDI) increasing globally, we investigated how obesity affects CDI outcomes. Previous studies have shown conflicting results, some link obesity to more severe disease, while others suggest a protective effect, the “obesity survival paradox”.
PML is a fatal CNS infection caused by the reactivation of JCV in ICHs. In this review, we discuss risk factors, clinical features, and propose a treatment algorithm based on current data and our experience. Emerging immunotherapies show promise.👇
link.springer.com/article/10.1...
Fungal infections in patients with hematologic malignancies in the pre-triazole era: The dawn of a new era in medical mycology
Umut Akova, Rachel Hicklen, Russell E. Lewis, Thomas J. Walsh, Dimitrios P. Kontoyiannis
@cmijournal.bsky.social
www.clinicalmicrobiologyandinfection.com/article/S119...
Pts with heme malignancies are at ⬆️ risk for severe COVID19. Vaccines are key preventive strategy, but the response is variable.
This review is based on the authors expert opinions informed by their experiences & literature search
doi.org/10.1080/174740…
Malignancy risk is higher among SOT recipients. 4 non-hepatitis viruses recognized as
oncogenic in SOT recipients (EBV,HHV8, HPV, Merkel cell polyomavirus).
This review discusses the prevention of #EBV & #HHV8 in SOT
👇
pmc.ncbi.nlm.nih.gov/articles/PMC...
#TxID
Hans Hirsch provided a master class in BKV as the keynote for the 5th @fredhutch.bsky.social Symposium on Infections in ICH. Studies have advanced our understanding of pathogens and management - but many questions remain.
The 2026 CDC yellow book on travel medicine is live at this link for those who are interested @davidofreedman.bsky.social books.google.com/books/about/...
Thrilled to join the #ESCMIDglobal 2025 Meet-the-expert session, discussing the impact of ageing metrics on infections and transplant outcomes in older adults. Key topics included immune senescence, infection risks, and vaccine efficacy for solid organ transplant recipients.
It was an honor to review the data on the link between Ureaplasma spp and Hyperammonemia in Lung Transplant recipients @ESCMID #ESCMIDGlobal 2025. Slides are here for those who want them.
www.dropbox.com/scl/fi/ei4ym...
Early Rx in Influenza is key!
While pts may not present to the hospital early after sx onset (median 3.6 days after sx onset), early empiric therapy for influenza is recommended by guidelines supported by a growing literature showing benefit but delays in therapy are common.
